Satsuma Pharmaceuticals, Inc.
STSADelisted Jun 8, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001692830
Satsuma Pharmaceuticals, Inc. was delisted on Jun 8, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 31 institutions reported holding it in 13F filings for Q1 2023, worth $12.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 31
- Q1 2023, −2 vs. previous quarter
- 13F value
- $12.7M
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding STSA, Q1 2023
No superinvestor reported holding STSA at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by Satsuma Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2023 (view filing) | Jun 6 | 2 days | Takanashi KenDirector, 10% Owner | PPurchaseCommon Stock, $0.0001 par value | +22.1M | $0.91 | +$20.1M | +789.3%24.8M after | |
| Jun 8, 2023 (view filing) | Jun 6-8 | 2 days | Shin Nippon Biomedical Laboratories, Ltd.10% Owner | PPurchase | +30.5M | $0.91 | +$27.7M | New position8.42M after | 2 lots |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +150.0K | $0.71 | +$106.5K | New position150.0K after | |
| Nov 16, 2022 (view filing) | Nov 14-15 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +6.44M | $0.6823 | +$4.39M | New position6.44M after | 3 lots |
| Nov 16, 2022 (view filing) | Nov 14 | 2 days | Commodore Capital LP10% Owner | SSaleCommon Stock, par value $0.0001 per share | −3.25M | $0.71 | −$2.31M | −87.6%461.3K after | |
| Nov 29, 2021 (view filing) | Nov 24 | 5 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +2.92K | $5.42 | +$15.8K | +0.1%3.71M after | |
| Nov 23, 2021 (view filing) | Nov 19-22 | 4 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +13.2K | $5.48 | +$72.3K | +0.4%3.71M after | 2 lots |
| Nov 12, 2021 (view filing) | Nov 10-11 | 2 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +17.6K | $5.94 | +$104.3K | +0.5%3.70M after | 2 lots |
| Nov 10, 2021 (view filing) | Nov 8 | 2 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +560 | $5.99 | +$3.35K | 0.0%3.68M after | |
| Nov 8, 2021 (view filing) | Nov 4-5 | 4 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +9.20K | $5.94 | +$54.6K | +0.3%3.68M after | 2 lots |
Top 10 13F holders, Q1 2023
The largest institutional positions in Satsuma Pharmaceuticals, Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 6,440,000 | $4.50M | 3.89% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 5,914,252 | $4.13M | 0.09% | 00.0% | Unchanged |
| NEA Management Company, LLC | 2,294,095 | $1.60M | 0.11% | −698,863−23.4% | Reduced |
| Vanguard Group Inc | 920,517 | $643.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 414,344 | $289.4K | 0.00% | +5,236+1.3% | Added |
| Lion Point Capital, LP | 319,742 | $223.3K | 0.12% | +319,742 | New |
| Two Sigma Investments, LP | 297,129 | $207.5K | 0.00% | +5,183+1.8% | Added |
| Two Sigma Advisers, LP | 274,000 | $191.4K | 0.00% | +121,700+79.9% | Added |
| Acadian Asset Management LLC | 275,069 | $191.0K | 0.00% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 177,900 | $124.3K | 0.08% | 00.0% | Unchanged |